Alumis Inc. Updates Estimates for LUMUS Clinical Trial

Alumis Inc. (NASDAQ: ALMS) recently disclosed revisions to its estimates for primary completion and study completion dates concerning the LUMUS clinical trial. The adjustments were made available on ClinicalTrials.gov on November 22, 2024.

The LUMUS trial is a global undertaking, comprising multiple centers, with a randomized, double-blind, placebo-controlled Phase 2 design. Its primary focus lies in evaluating the efficacy, safety, and pharmacokinetics of various doses of ESK-001 in adult patients diagnosed with systemic lupus erythematosus (SLE).

Alumis, in its statement, clarified that the updated information aligns with previously disclosed information present in its filings with the Securities and Exchange Commission and its prior public guidance. The organization explicitly stated that it holds no obligation to provide further updates to the forward-looking statements, except as compelled by law.

The document, submitted to the Securities and Exchange Commission in a Form 8-K filing, was signed by Alumis Inc.’s President and Chief Executive Officer, Martin Babler, on November 25, 2024.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Alumis’s 8K filing here.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.